Shares of Kamada Ltd. (KMDA) reached a 52-week high of $7.96 during intraday trading yesterday, reflecting investor optimism surrounding the company's continued growth and financial outlook for 2024 and 2025.
This commercial-stage global biopharmaceutical company is focused on specialty plasma-derived therapeutics.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com